13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001858703
Total reported value
$664.5M
$664.5M
72 檔
22.0%
In Q2 2025, Blue Owl Capital Holdings LP's U.S. equity holdings reached a combined market value of $664.5M, distributed across 72 disclosed stock positions.
Blue Owl Capital Holdings LP executed strategic sector rebalancing during Q2 2025, establishing 9 new positions while fully exiting 8 holdings and trimming 13 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NCDL | Nuveen Churchill Direct Lend | Stock-Other | 21.11% | -3.32% | — | |
| 2 | OBDC | Blue Owl Capital CORP | Stock-Financials | 9.46% | -2.73% | — | |
| 3 | CGEM | Cullinan Therapeutics Inc | Stock-Other | 5.80% | -3.07% | -2.05% | |
| 4 | EVCM | Evercommerce Inc | Stock-Other | 5.56% | — | — | |
| 5 | TRML | Tourmaline Bio Inc | Stock-Other | 5.15% | — | -3.86% | |
| 6 | LRMR | Larimar Therapeutics Inc | Stock-Other | 4.60% | -4.40% | +3.14% | |
| 7 | ✓ | Engene Holdings Inc | Stock-Other | 4.38% | -8.08% | EXIT | |
| 8 | CNDT | Conduent Inc | Stock-Other | 3.80% | -0.62% | -21.77% | |
| 9 | SGMT | Sagimet Biosciences Inc-a | Stock-Other | 3.27% | +1.00% | — | |
| 10 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 3.00% | -0.78% | +66.56% | |
| 11 | HLLY | Holley Inc | Stock-Other | 2.65% | -1.81% | -22.67% | |
| 12 | CVEO | Civeo CORP | Stock-Other | 2.37% | -1.28% | EXIT | |
| 13 | CMPX | Compass Therapeutics Inc | Stock-Other | 2.17% | -2.99% | -12.29% | |
| 14 | IRON | Disc Medicine Inc | Stock-Other | 2.09% | — | -12.83% | |
| 15 | ✓ | Ikena Oncology Inc | Stock-Other | 1.77% | — | — | |
| 16 | EYPT | Eyepoint Inc | Stock-Other | 1.71% | -1.52% | -29.46% | |
| 17 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 1.64% | — | — | |
| 18 | CNTX | Context Therapeutics Inc | Stock-Other | 1.57% | -3.34% | +0.54% | |
| 19 | RPTX | Repare Therapeutics Inc | Stock-Other | 1.54% | — | — | |
| 20 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 1.47% | — | +62.85% | |
| 21 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.40% | — | +4.95% | |
| 22 | TNGX | Tango Therapeutics Inc | Stock-Other | 1.35% | — | -61.61% | |
| 23 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 1.16% | -0.84% | -26.92% | |
| 24 | PLRX | Pliant Therapeutics Inc | Stock-Other | 1.11% | -1.01% | EXIT | |
| 25 | AQST | Aquestive Therapeutics Inc | Stock-Other | 0.98% | -0.91% | — | |
| 26 | PVLA | Palvella Therapeutics Inc | Stock-Other | 0.91% | -0.22% | -10.69% | |
| 27 | STWD | Starwood Property Trust Inc | Stock-Real Estate | 0.85% | -0.25% | — | |
| 28 | DELL | Dell Technologies -c | Stock-Tech | 0.82% | +1.53% | — | |
| 29 | BMEA | Biomea Fusion Inc | Stock-Other | 0.76% | — | — | |
| 30 | ✓ | Adc Therapeutics SA | Stock-Other | 0.63% | -0.58% | — | |
| 31 | FLD | Fold Holdings Inc | Stock-Other | 0.62% | -0.24% | — | |
| 32 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 0.56% | — | — | |
| 33 | CABA | Cabaletta Bio Inc | Stock-Other | 0.55% | +0.33% | NEW | |
| 34 | KRRO | Korro Bio Inc | Stock-Other | 0.50% | — | — | |
| 35 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.49% | — | — | |
| 36 | TTAN | Servicetitan Inc-a | Stock-Tech | 0.39% | — | — | |
| 37 | EPD | Enterprise Products Partners | Stock-Energy | 0.31% | -0.32% | EXIT | |
| 38 | MRKR | Marker Therapeutics Inc | Stock-Other | 0.27% | -0.07% | — | |
| 39 | CMPS | Compass Pathways PLC | Stock-Other | 0.21% | +0.96% | NEW | |
| 40 | ✓ | Stock-Other | 0.18% | — | — | ||
| 41 | ✓ | Alpha Modus Hldgs Inc | Stock-Other | 0.13% | -0.04% | EXIT | |
| 42 | ✓ | Rezolve Ai LTD | Stock-Other | 0.12% | -0.02% | -21.00% | |
| 43 | SLND-WS | Legato Merger CORP Ii -cw23 | Stock-Other | 0.09% | -0.01% | — | |
| 44 | CAH | Cardinal Health Inc | Stock-Healthcare | 0.09% | -0.10% | EXIT | |
| 45 | NIOBW | Niocorp Developments LTD -28 | Stock-Other | 0.09% | -0.08% | -28.71% | |
| 46 | AMODW | Insight Acquisition Co -cw23 | Stock-Other | 0.07% | -0.01% | — | |
| 47 | SHFS | Shf Holdings Inc | Stock-Other | 0.05% | -0.02% | — | |
| 48 | BKSY-WS | Blacksky Technology -cw24 | Stock-Other | 0.03% | — | — | |
| 49 | OPTXW | Omnilit Acquisition Cl A -23 | Stock-Other | 0.02% | -0.23% | EXIT | |
| 50 | DAVEW | Dave Inc -cw27 | Stock-Other | 0.02% | +0.01% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SGMT | Sagimet Biosciences Inc-a | +1.9% | — | Unchanged |
| 2 | TEM | Tempus Ai Inc-cl A | +1.6% | NEW | New buy |
| 3 | LRMR | Larimar Therapeutics Inc | +1.3% | +3.14% | Add |
| 4 | RARE | Ultragenyx Pharmaceutical In | +1.2% | +66.56% | Add |
| 5 | STWD | Starwood Property Trust Inc | +0.9% | NEW | New buy |
| 6 | DELL | Dell Technologies -c | +0.8% | NEW | New buy |
| 7 | BMEA | Biomea Fusion Inc | +0.8% | NEW | New buy |
| 8 | FLD | Fold Holdings Inc | +0.6% | NEW | New buy |
| 9 | CABA | Cabaletta Bio Inc | +0.6% | NEW | New buy |
| 10 | KRRO | Korro Bio Inc | +0.5% | NEW | New buy |
| 11 | APGE | Apogee Therapeutics Inc | +0.5% | NEW | New buy |
| 12 | RPTX | Repare Therapeutics Inc | +0.5% | — | Unchanged |
| 13 | MLYS | Mineralys Therapeutics Inc | +0.4% | +62.85% | Add |
| 14 | TNGX | Tango Therapeutics Inc | +0.4% | -61.61% | Trim |
| 15 | TTAN | Servicetitan Inc-a | +0.4% | NEW | New buy |
| 16 | CMPX | Compass Therapeutics Inc | +0.4% | -12.29% | Trim |
| 17 | EYPT | Eyepoint Inc | +0.3% | -29.46% | Trim |
| 18 | ✓ | Adc Therapeutics SA | +0.3% | — | Unchanged |
| 19 | EVCM | Evercommerce Inc | +0.2% | — | Unchanged |
| 20 | VRNA | Verona Pharma PLC - Adr | +0.2% | — | Unchanged |
| 21 | AQST | Aquestive Therapeutics Inc | +0.1% | — | Unchanged |
| 22 | CNTX | Context Therapeutics Inc | +0.1% | +0.54% | Add |
| 23 | ✓ | +0.1% | — | Unchanged | |
| 24 | ✓ | Rezolve Ai LTD | +0.1% | -21.00% | Trim |
| 25 | ✓ | Ikena Oncology Inc | +0.1% | — | Unchanged |
| 26 | TRML | Tourmaline Bio Inc | +0.1% | -3.86% | Trim |
| 27 | MRKR | Marker Therapeutics Inc | +0.1% | — | Unchanged |
| 28 | SLND-WS | Legato Merger CORP Ii -cw23 | +0.1% | — | Unchanged |
| 29 | SHFS | Shf Holdings Inc | -0.1% | — | Unchanged |
| 30 | 260 | Centessa Pharmaceuticals-adr | -0.1% | +4.95% | Add |
| 31 | ROIV | Roivant Sciences Ltd. | -0.1% | EXIT | Sold out |
| 32 | CGEM | Cullinan Therapeutics Inc | -0.2% | -2.05% | Trim |
| 33 | IRON | Disc Medicine Inc | -0.2% | -12.83% | Trim |
| 34 | PLRX | Pliant Therapeutics Inc | -0.2% | — | Unchanged |
| 35 | CVEO | Civeo CORP | -0.2% | -8.85% | Trim |
| 36 | OBDC | Blue Owl Capital CORP | -0.2% | — | Unchanged |
| 37 | GOCOQ | Gohealth Inc-class A | -0.2% | EXIT | Sold out |
| 38 | ✓ | Inozyme Pharma Inc | -0.3% | EXIT | Sold out |
| 39 | ✓ | Engene Holdings Inc | -0.4% | +13.68% | Add |
| 40 | PVLA | Palvella Therapeutics Inc | -0.4% | -10.69% | Trim |
| 41 | ✓ | Marblegate Acquisition Corp | -0.4% | EXIT | Sold out |
| 42 | NN | Nextnav Inc | -0.8% | EXIT | Sold out |
| 43 | ELDN | Eledon Pharmaceuticals Inc | -0.8% | -26.92% | Trim |
| 44 | CMPS | Compass Pathways PLC | -0.8% | -79.76% | Trim |
| 45 | KROS | Keros Therapeutics Inc | -0.9% | EXIT | Sold out |
| 46 | NCDL | Nuveen Churchill Direct Lend | -1% | — | Unchanged |
| 47 | ETWOGBP | E2open Parent Holdings Inc | -1.1% | EXIT | Sold out |
| 48 | CNDT | Conduent Inc | -1.2% | -21.77% | Trim |
| 49 | HLLY | Holley Inc | -1.8% | -22.67% | Trim |
| 50 | TQQQ | Proshares Ultrapro Qqq | -3.2% | EXIT | Sold out |
According to official SEC Form 13F filings, Blue Owl Capital Holdings LP reported a total U.S. public equity portfolio value of $664.5M across 72 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NCDL, OBDC, CGEM) accounted for 22.0% of total reported equity market value during Q2 2025.
Top New Position Initiated
TEM
市值: $5.1M
Top Position Liquidated / Trimmed
TQQQ
前期市值: $10.0M
During Q2 2025, Blue Owl Capital Holdings LP's top holdings by market value included NCDL (21.1%)、OBDC (9.5%)、CGEM (5.8%). The largest single position, NCDL, represented 21.1% of total portfolio value.
In Q2 2025, Blue Owl Capital Holdings LP made 36 total portfolio adjustments, initiating 9 new buys, adding to 6 positions, trimming 13 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.